Prostate-Specific Antigen Levels of Prostate Cancer Patients Three Months Following LHRH Agonist Therapy
Background: Luteinizing hormone-releasing hormone (LHRH) agonist therapy is an androgen suppression therapy aimed to treat prostate cancer by means chemical castration. Despite being frequently used in clinical setting, there is no prior study examining the of LHRH agonist drugs in Indonesia. This study aims to assess the efficacy of LHRH agonists in prostate cancer patients, measured by the reduction of serum prostate specific antigen (PSA) three months following treatment. Methods: The study used retrospective observational cohort design upon medical record of 83 prostate cancer patients in GatotSoebroto Army Hospital, Jakarta, Indonesia. We analyzed the recorded patients’ age, TNM staging, histologic grading, LHRH agonists used in therapy, along with the average baseline PSA level prior and three months following treatment. Paired T-test, Wilcoxon, ANOVA, and Kruskal-Wallis Test were used where appropriate. Results: We found significant change in PSA levels before and three-months following the use of LHRH agonists(p < 0.001), with the median decreasing from 56.20 (4.24-7,445.00) to 7.08 (0.01-942.00). Significant association was also found between PSA level prior to treatment and the prostate cancer groups according to stages (p < 0.001), histological grades (p = 0.020), and medications used (p = 0.010). However, this study found no significance of these groups in the PSA level reduction three months after therapy.
